STOCK TITAN

Supernus (SUPN) Rule 144 Filing for 25,000 Shares valued $1.2M

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Notice of proposed sale under Rule 144 for Supernus Pharmaceuticals, Inc. (SUPN) reports an intended sale of 25,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $1,200,000.00. The shares were acquired on 05/01/2012 as an in-kind distribution from NEA Partners. The filing lists total shares outstanding as 56,073,088, and an approximate sale date of 10/09/2025 on the NASDAQ. The filer also disclosed recent Rule 10b5-1 executed sales by Charles Newhall totaling 6,000 shares across three trades on 08/22/2025, 08/25/2025, and 08/27/2025

Positive

  • Brokered sale through Morgan Stanley indicates orderly execution channel for the 25,000 shares
  • Acquisition documented (in-kind distribution from NEA Partners on 05/01/2012), supporting ownership provenance

Negative

  • Insider selling activity: recent Rule 10b5-1 sales of 3,588, 1,412, and 1,000 shares occurred in 08/2025, totaling 6,000 shares
  • Represents potential dilution signal: 25,000 shares equal a measurable sale against 56,073,088 outstanding shares

Insights

Planned sale is formally disclosed and appears executed via broker and 10b5-1 plans.

The filing documents a proposed Rule 144 sale of 25,000 common shares valued at $1.2M, acquired by in-kind distribution from NEA Partners on 05/01/2012. The transaction is routed through Morgan Stanley Smith Barney LLC and slated for trading on NASDAQ on 10/09/2025.

Dependencies and compliance risks include adherence to Rule 144 timing/volume limits and the representational statement about no undisclosed material information. Recent 10b5-1 sales by the same account—totaling 6,000 shares in 08/2025—indicate prior executed sale activity; confirm plan adoption dates and broker instructions to validate Rule 10b5-1 reliance.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does SUPN Form 144 disclose about the sale?

The filing discloses a proposed sale of 25,000 common shares valued at $1,200,000.00, to be executed through Morgan Stanley Smith Barney LLC on 10/09/2025.

Who originally acquired the 25,000 shares listed on the SUPN Form 144?

The shares were acquired as an in-kind distribution from NEA Partners on 05/01/2012.

Are there recent related sales reported in the filing for SUPN?

Yes. The filing shows Rule 10b5-1 sales by Charles Newhall on 08/22/2025 (1,412 shares), 08/25/2025 (1,000 shares), and 08/27/2025 (3,588 shares), with combined gross proceeds reported.

How many SUPN shares are outstanding according to the filing?

The filing lists total shares outstanding as 56,073,088.

Which exchange will the SUPN shares be sold on?

The proposed sale is to occur on the NASDAQ exchange.
Supernus Pharma

NASDAQ:SUPN

SUPN Rankings

SUPN Latest News

SUPN Latest SEC Filings

SUPN Stock Data

2.94B
54.86M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ROCKVILLE